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Abstract
Pulmonary function loss in patients with Duchenne muscular dystrophy (DMD) is progressive and leads to pulmonary insufficiency. The
purpose of this study in 10–18 year old patients with DMD is the assessment of the inter-correlation between pulmonary function tests (PFTs),
their reliability and the association with the general disease stage measured by the Brooke score. Dynamic PFTs (peak expiratory flow [PEF],
forced vital capacity [FVC], forced expiratory volume in one second [FEV1]) and maximum static airway pressures (MIP, MEP) were
prospectively collected from 64 DMD patients enrolled in the DELOS trial (ClinicalTrials.gov, number NCT01027884). Baseline PEF percent
predicted (PEF%p) was <80% and patients had stopped taking glucocorticoids at least 12 months prior to study start. At baseline PEF%p, FVC%p
and FEV1%p correlated well with each other (Spearman’s rho: PEF%p–FVC%p: 0.54; PEF%p–FEV1%p: 0.72; FVC%p–FEV1%p: 0.91).
MIP%p and MEP%p correlated well with one another (MIP%p–MEP%p: 0.71) but less well with PEF%p (MIP%p–PEF%p: 0.40; MEP%p–
PEF%p: 0.41) and slightly better with FVC%p (MIP%p–FVC%p: 0.59; MEP%p–FVC%p: 0.74). The within-subject coefficients of variation (CV)
for successive measures were 6.97% for PEF%p, 6.69% for FVC%p and 11.11% for FEV1%p, indicating that these parameters could be more
reliably assessed compared to maximum static airway pressures (CV for MIP%p: 18.00%; MEP%p: 15.73%). Yearly rates of PFT decline (placebo
group) were larger in dynamic parameters (PEF%p: −8.9% [SD 2.0]; FVC%p: −8.7% [SD 1.1]; FEV1%p: −10.2% [SD 2.0]) than static airway
pressures (MIP%p: −4.5 [SD 1.3]; MEP%p: −2.8 [SD 1.1]). A considerable drop in dynamic pulmonary function parameters was associated with
loss of upper limb function (transition from Brooke score category 4 to category 5). In conclusion, these findings expand the understanding of the
reliability, correlation and evolution of different pulmonary function measures in DMD patients who are in the pulmonary function decline phase.
© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Duchenne muscular dystrophy (DMD), the most common
and severe form of muscular dystrophy, is characterized by
progressive respiratory muscle weakness which causes
restrictive respiratory disease, impaired clearance of airway
secretions, recurrent pulmonary infections due to ineffective
cough, hypoventilation and eventually respiratory failure [1–4].
Routine use of glucocorticoids (GCs), the introduction of
mechanical insufflation–exsufflation devices to improve airway
clearance and non-invasive ventilation to ameliorate alveolar
hypoventilation have become standard of care, which together
have increased the average life expectancy in DMD patients
[5–9]. Interestingly, a study of all-cause mortality showed that
the number of deaths due to respiratory failure was not
significantly influenced by the GC use status of patients [10].
Serial assessment of pulmonary function is a critical
element of recommended routine monitoring for patients with
DMD, as it may enable early identification and treatment of
pulmonary complications [11,12]. According to standard of care
recommendations [13] spirometry is required every 6 months,
recording dynamic pulmonary function parameters such as
forced vital capacity (FVC), forced expiratory volume in one
second (FEV1) and peak expiratory flow (PEF), a measure of
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expiratory muscle strength in patients without airway obstruction
[14]. Maximum static airway pressures (maximal inspiratory
pressure [MIP] and maximal expiratory pressure [MEP]) are also
measured frequently, particularly in early stages of the disease.
Although the assessment of pulmonary function decline in
DMD is important in routine patient care, there is still limited
knowledge about the correlation between these pulmonary
function parameters, their reliability and sensitivity to change
over time. Recent natural history data were reported in order to
better understand the influence of age, glucocorticoid use and
disease status on pulmonary function evolution in DMD.
Emerging evidence from these data indicates that in patients
with DMD (i) PEF and FVC expressed as percent of predicted
(PEF%p, FVC%p) are well correlated [15], (ii) GC use delays
the onset of pulmonary function loss, but once established, the
rate of decline is comparable between GC-users and patients
who are currently not using GCs [16–18], (iii) loss of FVC,
FEV1 and PEF expressed as percent predicted follow a linear
rate of decline from ~80% to ~30% [15,18,19] and (iv) the time
of loss of ambulation is a predictor of pulmonary function loss
[19]. Moreover, FVC%p, FEV1%p and PEF%p appear to
follow a more predictable and reliable change with age than
maximum static airway pressures (MIP%p, MEP%p) and peak
cough flow (PCF) [15,16].
Here we report pulmonary function data from a well-defined
DMD patient cohort (not using concomitant GC) prospectively
enrolled in a randomized, placebo-controlled, phase 3 clinical
trial (DELOS, Duchenne muscular dystrophy long-term
idebenone study) which demonstrated that idebenone, a short-
chain benzoquinone, significantly reduced the loss of pulmonary
function over the 52-week study period [20–22]. We have now
further analyzed cross sectional (baseline) data from all trial
participants and longitudinal data from the placebo group of
DELOS to determine the correlation between dynamic and static
pulmonary function outcomes, their inter-correlation as well as
correlation to upper limb function and the annual rate of change
with the goal to provide a comprehensive characterization of
pulmonary function in 10–18 year old patients with DMD who are
not taking concomitant GCs and further expand our understanding
of the natural course of pulmonary disease in DMD.
2. Patients and methods
2.1. Prospective data collection
Pulmonary function data were obtained from patients
participating in DELOS, a prospectively planned, multi-center,
phase 3 clinical trial evaluating the efficacy of idebenone
900 mg/day (Raxone®, Santhera Pharmaceuticals, Switzerland)
compared to placebo [20]. Patients were enrolled between July
2009 and December 2012 in study centers located in Belgium,
Germany, the Netherlands, Switzerland, France, Sweden,
Austria, Italy, Spain and the USA. The trial and any changes to
the protocol were approved by relevant national authorities
and the institutional review boards or independent ethics
committees in the countries of the participating centers and
conducted in accordance with good clinical practice and the
principles of the Declaration of Helsinki. Prior to any study-
related procedure, written informed consent was obtained from
all patients and/or parents or guardian. This study is registered
with ClinicalTrials.gov, number NCT01027884, and the overall
outcome was reported previously [20–22].
2.2. Patients
Patients aged 10–18 years with a documented and confirmed
diagnosis of DMD were eligible for enrollment. Study
participants had to have stopped taking glucocorticoids (GC) at
least 12 months prior to enrollment and were not allowed to
take GC during the 52-week study period. Furthermore, only
patients who had reached the stage of pulmonary function
decline, defined as PEF%p < 80% were enrolled. Based on their
PEF%p at baseline, study participants were stratified into two
subgroups (PEF%p <40% and 40–80%). Exclusion criteria
included: (i) dependence on assisted ventilation (non-invasive
nocturnal, daytime non-invasive or continuous invasive), (ii)
documented DMD-related hypoventilation for which assisted
ventilation is needed according to current standard of care
guidelines (e.g. FVC%p < 30%) and (iii) inability to form a
mouth seal to allow precise assessment of pulmonary function
and mouth pressures. Patients with symptomatic heart failure
(high probability of death within one year of baseline) and/or
symptomatic ventricular arrhythmias were also excluded from
the study. There were no selection criteria for ambulatory
status or for any dystrophin mutation type. The intent-to-treat
(ITT) population consisted of 64 patients; 33 patients were
randomized to the placebo group.
2.3. Pulmonary function tests
Pulmonary function tests (PFT) were performed during
hospital visits at screening, at baseline (within 6 weeks from
screening) and at weeks 13, 26, 39 and 52. FVC, FEV1 and
PEF were assessed using a Pneumotrac Spirometer 6800
(Vitalograph, UK). MIP and MEP were measured with a
MicroRPM instrument (Medical Supply Store, Chorley, UK).
All PFTs were performed with the aid of a qualified, trained
and certified operator and in accordance with the American
Thoracic Society/European Respiratory Society guidelines
[23]. At each study visit the PFTs were to be carried out in the
following sequence: PEF, FVC (which included FEV1), MIP
and MEP. For each pulmonary function parameter, the highest
value from a minimum of three and up to five consecutive
maneuvers was used for analysis. All PFT parameters were
normalized for height (derived from ulnar length [24,25]),
weight, age and race using established conversion equations as
shown in Supplementary material Table S1.
2.4. General disease status
The general disease status of patients was determined by
their ambulatory status and upper limb function. For this,
patients were counted as non-ambulatory if they were a non-
ambulant wheelchair user at baseline. Upper limb function
was assessed by the Brooke Upper Extremity scale [26], a
6-item scale where a higher score indicates a more severe
functional impairment of the upper limbs (Supplementary
material Fig. S1).
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2.5. Statistical analysis
Patient demographics were analyzed using descriptive
statistics (expressed as mean and standard deviation [SD]).
Yearly ‘rates of change’ of pulmonary function parameters for
the patients randomized to the placebo group of the study were
calculated as change from baseline to week 52 using a mixed
model for repeated measures (MMRM) with ‘visit’ as a fixed
factor in the model and ‘baseline assessment’ as a covariate
using SAS 9.3 (SAS Institute Inc., Cary, North Carolina, USA).
Data were presented as estimated mean change with standard
errors and 95% confidence intervals (CI); p-values indicate
whether the yearly change was significant. Within subject
coefficient of variation (CV) was calculated for assessments
conducted at screening and at baseline which were ≤6 weeks
apart. CV data and correlations between pulmonary function
parameters at baseline expressed as Spearman’s rho were
calculated using the software package R [27].
3. Results
3.1. Patient characteristics and general disease status
Patient characteristics at baseline for the ITT population and
for the placebo group are summarized in Table 1. The average
age of the ITT population was 14.3 years and patients were
either GC-naive (43.8%) or had used GC previously (56.3%)
but on average stopped their use 3.7 years prior to study
enrollment. Participating patients were already in an advanced
disease stage as seen in the high proportion of non-ambulant
patients (92.2%) and the overall high Brooke score of 4.2
points. Only 7 of 64 patients (10.9%) had a Brooke score of 1
or 2, but 38 of 64 (59.4%) patients had already reached
a Brooke score of 5 or 6 (Table 1) which implicates that
patients could no longer raise their hands to their mouth
(Supplementary material Fig. S1). The baseline characteristics
of the placebo subgroup and the subgroups of patients
separated by previous GC use status were generally comparable
to the ITT population. Interestingly, the subgroup of prior
GC-users was not different from GC-naive patients with respect
to general disease severity measured as proportion of non-
ambulant patients and Brooke upper extremity function score.
When patients were divided by the median age of the ITT
population (14 years) and the younger and older subgroups
compared, it became apparent that patients ≤14 years of age
were less advanced in their disease stage, seen in a smaller
proportion of non-ambulant patients (87.5%) and a lower
average Brooke score (3.8) compared to the subgroup of
patients >14 years (96.9% of non-ambulant patients; Brooke
score: 4.6).
3.2. Analysis of pulmonary function status
The vast majority of patients (81.3%) had PEF%p 40–80%
and only a small proportion (18.8%) had already very advanced
pulmonary function loss with PEF%p < 40% at baseline
(Table 2). A similar distribution between PEF%p strata at
baseline were seen for the placebo group, the subgroup of
non-ambulant patients and for patients irrespective of their
prior GC use status. Only when patients were separated by age,
a difference became apparent with more patients in the >14 year
Table 1
Baseline characteristics and general disease status.
Patient characteristics at baseline Patient population GC use status (prior GC-use) Ambulatory status Age category (by median)
ITT (N = 64) Placebo
(N = 33)







14.3 (2.7) 15.0 (2.5) 14.5 (2.9) 14.1 (2.5) 14.5 (2.6) 12.0 (1.2) 16.6 (1.5)
Weight (kg)
mean (SD)
58.7 (18.3) 61.9 (18.0) 59.5 (22.7) 58.1 (14.3) 60.4 (17.8) 51.1 (13.7) 66.4 (19.3)
Height (cm)*
mean (SD)
160.0 (12.0) 162.4 (12.4) 160.8 (13.7) 159.3 (10.7) 160.9 (11.7) 151.5 (9.4) 168.5 (7.6)
Non-ambulatory
N (%)
59 (92.2%) 31 (93.9%) 25 (89.3%) 34 (94.4%) 59 (100%) 28 (87.5%) 31 (96.9%)
Prior GC use
N (%)
No 28 (43.8%) 14 (42.4%) 28 (100.0%) 0 (0%) 25 (42.4%) 13 (40.6%) 15 (46.9%)
Yes 36 (56.3%) 19 (57.6%) 0 (0%) 36 (100.0%) 34 (57.6%) 19 (59.4%) 17 (53.1%)
Time since last GC use (years)
mean (SD)
3.7 (2.1) 4.3 (2.2) n.a. 3.7 (2.1) 3.6 (2.2) 3.0 (1.7) 4.4 (2.3)
Brooke score (N, %)
Score = 1 2 (3.1%) 0 (0.0%) 1 (3.6%) 1 (2.8%) 0 (0.0%) 2 (6.3%) 0 (0.0%)
Score = 2 5 (7.8%) 1 (3.0%) 2 (7.1%) 3 (8.3%) 3 (5.1%) 4 (12.5%) 1 (3.1%)
Score = 3 9 (14.1%) 4 (12.1%) 3 (10.7%) 6 (16.7%) 8 (13.6%) 6 (18.8%) 3 (9.4%)
Score = 4 10 (15.6%) 7 (21.2%) 6 (21.4%) 4 (11.1%) 10 (16.9%) 6 (18.8%) 4 (12.5%)
Score = 5 37 (57.8%) 21 (63.6%) 15 (53.6%) 22 (61.1%) 37 (62.7%) 14 (43.8%) 23 (71.9%)
Score = 6 1 (1.6%) 0 (0.0%) 1 (3.6%) 0 (0.0%) 1 (1.7%) 0 (0.0%) 1 (3.1%)
Mean (SD) 4.2 (1.2) 4.5 (0.8) 4.3 (1.2) 4.2 (1.2) 4.4 (0.9) 3.8 (1.3) 4.6 (0.8)
Data are means (SD) from descriptive statistics.
* Derived from ulnar length according to Gauld et al. (2003); Gauld et al. (2004).
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subgroup (28.1%) having PEF%p below 40% at baseline
compared to the subgroup of patients ≤14 years (9.4%).
Average baseline pulmonary function data of dynamic flow-
(PEF%p) and volume-related parameters (FVC%p; FEV1%p)
were comparable between the ITT population, the subgroup
of non-ambulant patients, the GC-naive patients and the
subgroup of patients who previously used GC. Only MEP and
MEP%p were significantly higher in the previous GC-user
group compared to patients who never used GC (statistical test
for difference according to GC use status: MEP: p = 0.011;
MEP%: p = 0.018). The subgroup of younger patients (≤14
years) generally had higher PFT values indicating a better
pulmonary function status compared to patients in the older
(>14 years) subgroup (statistical test for difference between age
categories for percent predicted PFTs: PEF%p: p = 0.068;
FVC%p: p < 0.0001; FEV1%p: p < 0.0001; MIP%p: p = 0.007;
MEP%p: p < 0.0001). The Tiffeneau index calculated as the
ratio of FEV1/FVC and a measure of airway obstruction was in
the normal range in all populations studied indicating the
restrictive and not obstructive nature of pulmonary function
loss in DMD patients. Following a recent proposal for the use of
modified ATS criteria in DMD patients [18], we assessed how
many patients had differences of >10% between the highest
two FVC values (measured in liters) at baseline. There were
6 patients (all randomized to the idebenone group) who had
>10% difference between their highest two FVC values at
baseline (mean difference: 14.9%; SD: 4.3%). The mean
difference between the highest two FVC values at baseline was
3.8% (SD 4.5%) for the ITT population and 2.7% (SD: 2.4%)
when the 6 patients with differences of >10% between the two
highest FVC values were excluded from the ITT population.
3.3. Correlation of pulmonary function parameters and
reliability of their assessment
At baseline, dynamic flow- (PEF%p) and volume-related
(FVC%p, FEV1%p) pulmonary function outcomes correlated
well with one another (Fig. 1) as reflected by their good inter-
correlation using Spearman’s rho coefficients: PEF%p–
FVC%p: 0.54; PEF%p–FEV1%p: 0.72; FEV1%p–FVC%p:
0.91. Not surprisingly, the strongest correlation was observed
between FVC%p and FEV1%p, both representing volume-
related pulmonary function outcomes. Maximum static airway
pressures (MIP%p; MEP%p) correlated well with one another
at baseline (MIP%p–MEP%p: 0.71) but less well with the flow-
related parameter (MIP%p–PEF%p: 0.40; MEP%p–PEF%p:
0.41) and slightly better with the volume-related parameter
(MIP%p–FVC%p: 0.59; MEP%p–FVC%p: 0.74). The good
inter-correlation between PEF%p, FVC%p and FEV1%p was
confirmed for the change from baseline to week 52 in the
placebo group (Spearman’s rho coefficients: PEF%p–FVC%p:
0.60; PEF%p–FEV1%p: 0.79; FEV1%p–FVC%p: 0.73).
The within-subject coefficient of variation (CV) was
assessed between the screening and baseline visits, which
took place on an average of 16.7 days (SD 12.4) apart.
The resulting CVs from screening to baseline measures
indicated that the most reliably assessed pulmonary function
outcomes were FVC%p (CV: 6.69%) and PEF%p (CV: 6.97%)
followed by FEV1%p (CV: 11.11%) (Table 3). In contrast,
CVs for maximum static airway pressures were considerably
higher (MIP%p: 18.0%; MEP%p: 15.4%) indicating patients’
difficulties to reliably reproduce these measures. CVs were also
analyzed for the subgroups of patients ≤14 or >14 years of age
Table 2
Pulmonary function status at baseline.
Patient characteristics
at baseline
Patient population GC use status (prior GC-use) Ambulatory status Age category (by median)
ITT (N = 64) Placebo
(N = 33)
No (N = 28) Yes (N = 36) Non ambulant
(N = 59)
≤14 y (N = 32) >14 y (N=32)
PEF %p strata
PEF 40%–80% 52 (81.3%) 26 (78.8%) 23 (82.1%) 29 (80.6%) 47 (79.7%) 29 (90.6%) 23 (71.9%)
PEF < 40% 12 (18.8%) 7 (21.2%) 5 (17.9%) 7 (19.4%) 12 (20.3%) 3 (9.4%) 9 (28.1%)
Baseline PFT
PEF [L/min] 226.0 (54.7) 233.8 (59.6) 232.9 (51.8) 220.6 (57.0) 225.7 (55.7) 212.3 (45.3) 239.6 (60.3)
PEF%p 53.8 (11.8) 54.2 (13.2) 55.2 (10.9) 52.8 (12.5) 53.1 (12.0) 56.5 (10.9) 51.2 (12.2)
FVC [L] 1.9 (0.5) 1.9 (0.5) 1.8 (0.5) 1.9 (0.5) 1.9 (0.5) 1.9 (0.4) 1.8 (0.6)
FVC%p 52.8 (18.1) 50.4 (20.0) 51.5 (19.1) 53.8 (17.5) 51.6 (18.0) 64.5 (15.0) 41.1 (12.7)
FEV1 [L] 1.6 (0.5) 1.6 (0.5) 1.6 (0.4) 1.6 (0.5) 1.6 (0.5) 1.6 (0.4) 1.5 (0.6)
FEV1%p 51.4 (18.5) 49.5 (20.6) 52.0 (18.9) 51.0 (18.4) 49.9 (18.2) 62.4 (15.5) 40.5 (14.5)
Tiffeneau index 0.8 (0.1) 0.9 (0.1) 0.9 (0.1) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1) 0.8 (0.1)
MIP 45.9 (20.8) 44.6 (16.9) 45.1 (15.2) 46.6 (24.4) 46.8 (20.8) 47.4 (20) 44.5 (21.7)
MIP %p 41 (19.6) 38.5 (16.9) 40.0 (15.4) 41.7 (22.6) 41.2 (19.6) 47.4 (19.8) 34.5 (17.5)
MEP 40.1 (16.0) 39.7 (16.6) 34.7 (11.6) 44.4 (17.8) 39.8 (16.4) 42.6 (14.5) 37.7 (17.3)
MEP %p 26.6 (12.2) 25.1 (12.2) 22.8 (9.4) 29.7 (13.3) 25.9 (12.2) 32.5 (11.4) 20.8 (10.1)
Data are means (SD) from descriptive statistics. For convenience, data for MIP and MIP%p are also presented as positive values. The Tiffeneau Index is calculated
as FEV1/FVC.
Table 3







PEF%p 6.97 6.63 7.29
FVC%p 6.69 8.40 4.36
FEV1%p 11.11 9.75 12.32
MIP%p 18.00 20.74 14.76
MEP%p 15.73 17.76 13.47
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to assess the influence of age on the ability to perform PFTs.
Table 3 also shows that from all available PFTs the lowest CV
was measured for PEF%p in the ≤14 year group but for FVC%p
in the >14 year group.
In an exploratory analysis the CVs were also calculated for
a subpopulation of 58 patients, excluding 6 patients with >10%
difference between their highest two FVC values at baseline
according to Ref. [18]. The resulting CVs for this subpopulation
(N = 58) were comparable to the CVs of the ITT population
(N = 64) except for lower CV in FVC%, as expected in this
modified population (Supplementary material Table S2). We
also determined the CVs of PFTs for the ITT population
with patients separated by baseline Brooke score category
(patients in Brooke score categories 1–4: N = 26; Brooke score
categories 5,6: N = 38). As shown in Supplementary material
Table S3 the CVs for PEF%p and FVC%p were comparable
between the two Brooke score subgroups (difference <0.5%),
demonstrating again the reliability of these two PFT outcome
measures irrespective of the general disease status. In contrast,
CVs for FEV1%p, MIP%p and MEP%p differed by more than
3% between these Brooke score subgroups.
3.4. Yearly rate of change in pulmonary function parameters
of untreated patients
In order to assess the natural course of disease progression in
untreated DMD patients, analyses on the yearly rate of change
were conducted for the placebo group of the DELOS trial
(N = 33). All flow- (PEF%p) and volume-related (FVC%p;
FEV1%p) dynamic pulmonary function parameters showed a
statistically significant decline over the course of one year
(Table 4). Changes of similar magnitude were observed when
patients were split into subgroups of GC-naive patients and
those who previously used GC but had stopped at least one
year prior to study start. Similarly, the yearly change was
comparable in the subgroups split according to the median age
at baseline (14 years). Graphical presentations further illustrate
the similarity in the change over time in flow- (PEF%p) and
volume-related (FVC%p; FEV1%p) PFTs in subgroups split by
previous GC use status (Supplementary material Fig. S2)
and age category (Supplementary material Fig. S3). These
findings demonstrate that age and previous GC use are not
discriminating factors for pulmonary disease progression in
patients who are in the pulmonary function decline phase (i.e.
patients with PEF%p < 80% at the time of enrollment). For
MIP%p the yearly rate of decline was slightly smaller in
previous GC-users and in the younger age subgroup compared
to GC-naive patients and those of older age. MEP%p showed an
opposite trend, with larger yearly decline in the previous
GC-users and the younger patient subgroup. However, the
clinical interpretation of these small differences is unclear.
Overall, the yearly decline in maximum static airway pressures
was only about half of the magnitude as seen for the dynamic
PFT parameters PEF%p, FVC%p and FEV1%p.
3.5. Correlation between pulmonary function and general
disease stage
In an attempt to correlate PFTs with general disease
progression in this predominantly non-ambulant population,
baseline PEF%p, FVC%p and FEV1%p were analyzed
separated by a Brooke upper extremity score category (Fig. 2).
Although the interpretation of these data is limited by the small
number of patients per Brooke score category, a marked drop in
all three PFT parameters is apparent at the transition between
Brooke score categories 4 and 5. While patients with Brooke
scores 1–4 (on average) had PFT results of around 60%–80% of
predicted, all average PFTs dropped when patients lost the
Fig. 1. Baseline correlation between dynamic pulmonary function test
outcomes. Individual patient data are represented by dots (with regression line);
shaded area: 95% confidence interval band.
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ability to raise their hand to their mouth (Brooke score 5); this
was particularly evident for the volume-related parameters
FVC%p and FEV1%p. Available data for Brooke score
category 6 were too limited to allow further interpretation of the
data.
4. Discussion
This work provides pulmonary function data from a
prospectively planned intervention study which enrolled 10–18
year old DMD patients who were in pulmonary function decline
stage (defined as PEF%p < 80%) and who did not use
glucocorticoids at least 12 months prior to the first assessment
(baseline) and during a 12-month follow-up period. Most
patients in this study were non-ambulant. Although the
interpretation of the data shown here is limited by the sample
size (N = 64) and the post-hoc nature of some of the analyses
presented, this study with prospective and rigorous data
acquisition nevertheless adds to the understanding of the
reliability of PFT assessments in adolescent, mostly non-
ambulant DMD patients, the natural course of PFT changes and
the relation to the general disease status assessed by the Brooke
upper extremity function scale.
4.1. Correlation of pulmonary function parameters and
reliability of their assessment
Although pulmonary function decline in DMD is typically in
a restrictive pattern with low FVC and a normal FEV1/FVC
ratio (Tiffeneau index), this work and previous data [15,18]
indicate that flow- and volume-related dynamic parameters
follow a similar pattern during disease progression and are
highly correlated. When expressed as percent of predicted to
account for maturational changes PEF%p, FVC%p and
FEV1%p are highly correlated and decline approximately
linearly with increasing age once patients enter the pulmonary
function decline stage. This good correlation between flow- and
volume-related parameters has been documented previously
[28,29] and is of clinical interest as decline in FVC is an
established predictor of morbidity [30]. In the absence of
obstructive lung disease, PEF appears to be an equally valuable
measure of disease monitoring and progression of pulmonary
function loss in DMD as it assesses maximal expiratory effort
as a surrogate measure for expiratory muscle strength.
Our data confirm that in 10–18 year old boys with DMD,
PEF%p, FVC%p and FEV1%p can be reliably assessed as seen
by the low within-subject CV for assessments taken on an
average of 16.7 days (SD 12.4) apart. The two PFT parameters
with the best CV (CV: ~7%) were FVC%p and PEF%p,
followed by FEV1%p (CV: ~11%). In contrast, CVs for
maximum static airway pressures were considerably higher,
which may limit the use of MIP%p and MEP%p as pulmonary
outcome measures for patients who have reached teenage years.
This is in agreement with previous work, which demonstrated
that MIP%p and MEP%p did initially decline in patients
younger than 15 years and later increased again in patients from
the age of 15 years [16]. As shown here, MIP%p and MEP%p
consistently have high CVs irrespective of age category or
general disease stage and consequently have to be considered
less reliable PFTs compared to FVC%p and PEF%p, which has
to be considered in clinical interpretation of data obtained from
patients in their teenage years.
4.2. Pulmonary function status and evolution is not
influenced by previous use of glucocorticoids
There is general agreement that patients with DMD benefit
from GC treatment [31,32], which has become the mainstay of
neuromuscular management in DMD [33,34]. Specifically, the
effect of GC on muscle strength has been shown to prolong
ambulation by several years and more recently, continued
treatment with GC after the patient becomes non-ambulant has
also shown to reduce the risk of progressive scoliosis, stabilize
pulmonary function [17,35–37] and delay the loss of upper limb
function [38]. An interesting finding of this work was the
observation that previous GC use had no long-lasting effect on
the decline in pulmonary function. Specifically, patients who
had stopped taking GCs at least 12 months and on average
3.7 years prior to the first PFT assessment (i.e. baseline) had
Table 4
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Data are estimated means from MMRM (SEM) and 95% confidence intervals; p-values indicate whether the yearly change was significant.
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PEF%p, FVC%p and FEV1%p comparable to patients who had
never used GCs. This is in agreement with previously published
data showing that use of GCs can delay the start of pulmonary
function decline by 2–3 years [17], but once established, GC
use does not alter the rate of decline of pulmonary function,
which continues linearly and unabated from the age of
approximately 10 years through to the early twenties [17,18].
This is important in light of the well-described risks associated
with chronic administration of GCs such as growth retardation,
bone demineralization and increased fracture risk, obesity,
hypertension and cataracts, among others [33]. In a natural
history study, 42% of DMD patients aged 10 years and older
had never used GCs or discontinued their use because of side-
effects and tolerability limitations [17], with this proportion
increasing in the post-ambulatory phase of the disease.
4.3. Correlation of pulmonary function status with general
disease status
Similar to PFT measures, we also found no apparent
difference in average Brooke upper extremity function score
between past GC-users and GC-naive patients, which is in line
with earlier data [17]. An interesting finding of this work was
the observation that pulmonary function drops in patients who
have reached a Brooke upper extremity function sore of 5,
which is in general agreement with earlier data indicating a
correlation between upper extremity function loss and decline
in FVC [1]. This finding may be of clinical relevance, as it
indicates that patients who lose their ability to raise their hand
to their mouth may have reached a clinically relevant threshold
of lung volume (i.e. FVC%p of 50%), which could be used as
an easy-to-assess indicator to identify patients who have
reached the stage of advanced pulmonary function loss.
In summary, prospectively collected cross-sectional and
longitudinal data from a controlled, multi-center study
contribute to the understanding of pulmonary outcome
measures in pediatric and adolescent patients with DMD, their
correlation and reliability of assessment and their association
with general disease status and yearly rate of change. Although
the yearly change in FVC%p reported here appears to be most
consistent with what is known and accepted in the field,
also PEF%p appears to be a reliable marker of flow-related
pulmonary function and relevant to provide a comprehensive
assessment of the pulmonary function status and decline over
time in patients with DMD.
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Fig. 2. Pulmonary function by Brooke upper limb function score. Boxplots
show medians (quartiles) from descriptive statistics. Brooke category is shown
on the X-axis and pulmonary function data as percent predicted on the Y-axis.
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